{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T07:40:17Z","timestamp":1719128417450},"reference-count":78,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2006,8,31]]},"DOI":"10.2217\/14796694.2.4.515","type":"journal-article","created":{"date-parts":[[2006,8,21]],"date-time":"2006-08-21T14:36:30Z","timestamp":1156170990000},"page":"515-524","source":"Crossref","is-referenced-by-count":0,"title":["Practical Management of Classical Myeloproliferative Disorder Patients: A Clinician\u2018s Guide"],"prefix":"10.1080","volume":"2","author":[{"given":"Ruben A","family":"Mesa","sequence":"first","affiliation":[{"name":"Mayo Clinic, Division of Hematology &amp; Internal Medicine, 200 First Street, SW Rochester, MN55905, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2006,8,21]]},"reference":[{"key":"e_1_3_1_3_1_1","doi-asserted-by":"publisher","DOI":"10.4065\/73.12.1177"},{"key":"e_1_3_1_3_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2226"},{"key":"e_1_3_1_3_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199809000-00004"},{"key":"e_1_3_1_3_4_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996109"},{"key":"e_1_3_1_3_5_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00342.x"},{"key":"e_1_3_1_3_6_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.3.801"},{"key":"e_1_3_1_3_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"e_1_3_1_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(00)00020-1"},{"key":"e_1_3_1_3_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.1013.1013"},{"key":"e_1_3_1_3_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02796.x"},{"key":"e_1_3_1_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3374"},{"key":"e_1_3_1_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21644"},{"key":"e_1_3_1_3_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05776.x"},{"key":"e_1_3_1_3_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3073124.x"},{"key":"e_1_3_1_3_15_1","first-page":"2831","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European\u00a0group for Blood and Marrow Transplantation\u00a0Societe Francaise de Greffe\u00a0de Moelle\u00a0Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study","volume":"93","author":"Guardiola P","year":"1999","unstructured":"Guardiola P , AndersonJE, BandiniGet al.: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European\u00a0group for Blood and Marrow Transplantation\u00a0Societe Francaise de Greffe\u00a0de Moelle\u00a0Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood93, 2831\u20132838 (1999).","journal-title":"Blood"},{"key":"e_1_3_1_3_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1856"},{"key":"e_1_3_1_3_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4299"},{"key":"e_1_3_1_3_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05373.x"},{"key":"e_1_3_1_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2255"},{"key":"e_1_3_1_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"e_1_3_1_3_21_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.2.159"},{"key":"e_1_3_1_3_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401270"},{"key":"e_1_3_1_3_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.05.023"},{"key":"e_1_3_1_3_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb08272.x"},{"key":"e_1_3_1_3_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.556"},{"key":"e_1_3_1_3_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V64.5.981.981"},{"key":"e_1_3_1_3_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3426"},{"key":"e_1_3_1_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2005.01.001"},{"key":"e_1_3_1_3_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_3_1_3_30_1","first-page":"166","volume-title":"Polycythemia Vera and the Myeloproliferative Disorders.","author":"Berk PD","year":"1995","unstructured":"Berk PD , WassermanLR, FruchtmanSM, GoldbergJD: Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In:Polycythemia Vera and the Myeloproliferative Disorders. Wasserman LR, Berk PD, Berlin\u00a0NI (Eds). WB Saunders, PA, USA 166\u2013194 (1995)."},{"key":"e_1_3_1_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"e_1_3_1_3_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2002.03367.x"},{"key":"e_1_3_1_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_3_1_3_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_3_1_3_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-1-199801010-00005"},{"key":"e_1_3_1_3_36_1","first-page":"40","article-title":"Interferon-\u03b1: effects of long-term treatment for polycythemia vera.","volume":"34","author":"Silver RT","year":"1997","unstructured":"Silver RT : Interferon-\u03b1: effects of long-term treatment for polycythemia vera.Semin. Hematol.34, 40\u201350 (1997).","journal-title":"Semin. Hematol."},{"key":"e_1_3_1_3_37_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996123"},{"key":"e_1_3_1_3_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.2.234"},{"key":"e_1_3_1_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21900"},{"key":"e_1_3_1_3_40_1","first-page":"1333","article-title":"Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a Phase II study","volume":"90","author":"Langer C","year":"2005","unstructured":"Langer C , LengfelderE, ThieleJet al.: Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a Phase II study. Haematologica90, 1333\u20131338 (2005).","journal-title":"Haematologica"},{"key":"e_1_3_1_3_41_1","first-page":"616","article-title":"rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.","volume":"83","author":"Rodriguez JN","year":"1998","unstructured":"Rodriguez JN , MartinoML, DieguezJC, PradosD: rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.Haematologica83, 616\u2013621 (1998).","journal-title":"Haematologica"},{"key":"e_1_3_1_3_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05229.x"},{"key":"e_1_3_1_3_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05524.x"},{"key":"e_1_3_1_3_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02918.x"},{"key":"e_1_3_1_3_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03072.x"},{"key":"e_1_3_1_3_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03443.x"},{"key":"e_1_3_1_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.4007"},{"key":"e_1_3_1_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"e_1_3_1_3_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.2576.2576"},{"key":"e_1_3_1_3_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00386.x"},{"key":"e_1_3_1_3_51_1","first-page":"104","article-title":"Durable and unmaintained remissions with Thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: long term outcome analysis of two prospective trials.","volume":"102","author":"Mesa RA","year":"2003","unstructured":"Mesa RA , ElliottMA, FaoroL, TefferiA: Durable and unmaintained remissions with Thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: long term outcome analysis of two prospective trials.Blood102, 104 (2003).","journal-title":"Blood"},{"key":"e_1_3_1_3_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004572"},{"key":"e_1_3_1_3_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3665"},{"key":"e_1_3_1_3_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20509"},{"key":"e_1_3_1_3_55_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.10.1223"},{"key":"e_1_3_1_3_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.4007"},{"key":"e_1_3_1_3_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00212.x"},{"key":"e_1_3_1_3_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1984.tb00724.x"},{"key":"e_1_3_1_3_59_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2001.03331.x"},{"key":"e_1_3_1_3_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00370.x"},{"key":"e_1_3_1_3_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.1510.1510"},{"key":"e_1_3_1_3_62_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00998.x"},{"key":"e_1_3_1_3_63_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03695.x"},{"key":"e_1_3_1_3_64_1","doi-asserted-by":"publisher","DOI":"10.1159\/000204873"},{"key":"e_1_3_1_3_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2864"},{"key":"e_1_3_1_3_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21297"},{"key":"e_1_3_1_3_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_3_1_3_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_3_1_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_3_1_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_3_1_3_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_3_1_3_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02609.x"},{"key":"e_1_3_1_3_73_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00833.x"},{"key":"e_1_3_1_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.10.002"},{"key":"e_1_3_1_3_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2319"},{"key":"e_1_3_1_3_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000040008"},{"key":"e_1_3_1_3_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00212.x"},{"key":"e_1_3_1_3_78_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3843198.x"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14796694.2.4.515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:57Z","timestamp":1719124977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14796694.2.4.515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,21]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8,31]]}},"alternative-id":["10.2217\/14796694.2.4.515"],"URL":"https:\/\/doi.org\/10.2217\/14796694.2.4.515","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,21]]}}}